{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:16:08Z","timestamp":1767485768544,"version":"3.48.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06531-7","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:34:19Z","timestamp":1765413259000},"page":"6327-6337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting the toxicity-efficacy ratio of venetoclax in real-world patients"],"prefix":"10.1007","volume":"104","author":[{"given":"Lo\u00efc","family":"Osanno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Brocque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Delpech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Farnault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Colle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Chiaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Izard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gis","family":"Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Dacos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chems","family":"Djezzar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffroy","family":"Venton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00eblle","family":"Fanciullino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"9","key":"6531_CR1","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/cncr.22233","volume":"107","author":"B Deschler","year":"2006","unstructured":"Deschler B, L\u00fcbbert M (2006) Acute myeloid leukemia: epidemiology and etiology. Cancer 107(9):2099\u20132107","journal-title":"Cancer"},{"key":"6531_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70\u201387","journal-title":"Blood Rev"},{"issue":"11","key":"6531_CR3","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","volume":"103","author":"VV Prassek","year":"2018","unstructured":"Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B et al (2018) Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica 103(11):1853\u20131861","journal-title":"Haematologica"},{"issue":"7","key":"6531_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"11","key":"6531_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","volume":"27","author":"P Vachhani","year":"2022","unstructured":"Vachhani P, Flahavan EM, Xu T, Ma E, Montez M, Gershon A et al (2022) Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US. Oncologist 27(11):907\u2013918","journal-title":"Oncologist"},{"issue":"2","key":"6531_CR6","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1002\/ajh.27180","volume":"99","author":"O Karrar","year":"2024","unstructured":"Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A et al (2024) Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival. Am J Hematol 99(2):E63\u2013E66","journal-title":"Am J Hematol"},{"issue":"11","key":"6531_CR7","doi-asserted-by":"publisher","first-page":"E416","DOI":"10.1002\/ajh.26692","volume":"97","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M et al (2022) Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol 97(11):E416\u2013E419","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"6531_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2022-165464","volume":"140","author":"C Willekens","year":"2022","unstructured":"Willekens C, Chraibi S, Decroocq J, Carpentier B, Lebon D, Bonnet S et al (2022) Reduced venetoclax exposition to seven days of Azacitidine is efficient in treatment-na\u00efve patients with acute myeloid leukemia. Blood 140(Supplement 1):537\u2013538","journal-title":"Blood"},{"issue":"3","key":"6531_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T, Miyagishima T (2023) Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol 102(3):541\u2013546","journal-title":"Ann Hematol"},{"issue":"12","key":"6531_CR10","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","volume":"41","author":"M Garc\u00eda-Ferrer","year":"2019","unstructured":"Garc\u00eda-Ferrer M, Wojnicz A, Mej\u00eda G, Koller D, Zubiaur P, Abad-Santos F (2019) Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: A systematic review and Meta-analysis. Clin Ther 41(12):2558\u20132570e7","journal-title":"Clin Ther"},{"issue":"4","key":"6531_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cpdd.395","volume":"7","author":"TT Cheung","year":"2018","unstructured":"Cheung TT, Salem AH, Menon RM, Munasinghe WP, Bueno OF, Agarwal SK (2018) Pharmacokinetics of the BCL-2 inhibitor venetoclax in healthy Chinese subjects. Clin Pharmacol Drug Dev 7(4):435\u2013440","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"6531_CR12","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/molecules27051607","volume":"27","author":"X Yang","year":"2022","unstructured":"Yang X, Mei C, He X, He L, Lu X, Tong H et al (2022) Quantification of venetoclax for therapeutic drug monitoring in Chinese acute myeloid leukemia patients by a validated UPLC-MS\/MS method. Molecules 27(5):1607","journal-title":"Molecules"},{"key":"6531_CR13","unstructured":"Recherches n\u2019impliquant pas la personne humaine \u00e9tudes et \u00e9valuations dans le domaine de la sant\u00e9 [Internet]. [cited 2023 Aug 22]. Available from: https:\/\/www.cnil.fr\/fr\/declaration\/mr-004-recherches-nimpliquant-pas-la-personne-humaine-etudes-et-evaluations-dans-le"},{"issue":"20","key":"6531_CR14","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"12","key":"6531_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"key":"6531_CR16","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. [cited 2023 Aug 29]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_60"},{"key":"6531_CR17","unstructured":"ich-guideline-m10 -bioanalytical-method-validation-study-sample-analysis-frequently-asked-questions_en.pdf [Internet]. [cited 2023 May 22]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-study-sample-analysis-frequently-asked-questions_en.pdf"},{"issue":"2","key":"6531_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/ph14020119","volume":"14","author":"RAG van Eerden","year":"2021","unstructured":"van Eerden RAG, Oomen-de Hoop E, Noordam A, Mathijssen RHJ, Koolen SLW (2021) Feasibility of extrapolating randomly taken plasma samples to trough levels for therapeutic drug monitoring purposes of small molecule kinase inhibitors. Pharmaceuticals (Basel) 14(2):119","journal-title":"Pharmaceuticals (Basel)"},{"key":"6531_CR19","unstructured":"Kassambara A, Kosinski M, Biecek P (2024) _survminer: Drawing Survival Curves using \u2019ggplot2\u2019_. R package version 0.5.0.999. https:\/\/github.com\/kassambara\/survminer"},{"issue":"1","key":"6531_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2307\/2532740","volume":"48","author":"B Lausen","year":"1992","unstructured":"Lausen B, Schumacher M (1992) Maximally selected rank statistics. Biometrics 48(1):73\u201385","journal-title":"Biometrics"},{"issue":"2","key":"6531_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA et al (2017) Management of Venetoclax-Posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther 39(2):359\u2013367","journal-title":"Clin Ther"},{"issue":"8","key":"6531_CR22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/jcph.2248","volume":"63","author":"JQX Gong","year":"2023","unstructured":"Gong JQX, Suleiman AA, Menon R, Deng R, Mensing S, Salem AH (2023) Pooled population pharmacokinetic analyses of venetoclax in patients across indications and healthy subjects from phase 1, 2, and 3 clinical trials. J Clin Pharmacol 63(8):950\u2013960","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"6531_CR23","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","volume":"18","author":"AK Jones","year":"2016","unstructured":"Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH (2016) Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin\u2019s lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J 18(5):1192\u20131202","journal-title":"AAPS J"},{"issue":"2","key":"6531_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hon.2964","volume":"40","author":"D Brackman","year":"2022","unstructured":"Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD et al (2022) Venetoclax exposure-efficacy and exposure\u2010safety relationships in patients with treatment\u2010na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematol Oncol 40(2):269\u2013279","journal-title":"Hematol Oncol"},{"issue":"7","key":"6531_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","volume":"4","author":"H Burger","year":"2005","unstructured":"Burger H, van Tol H, Brok M, Wiemer EAC, de Bruijn EA, Guetens G et al (2005) Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4(7):747\u2013752","journal-title":"Cancer Biol Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06531-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06531-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06531-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:20Z","timestamp":1767485720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06531-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6531"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06531-7","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}